Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer - Summary - MDSpire
Clinical Guidelines
Feature

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

  • By

  • Julia Cipriano

  • May 5, 2026

  • 15 min

Share

The phase II BRCAAway trial revealed that first-line treatment combining abiraterone, prednisone, and olaparib achieved a median overall survival of over 5 years in patients with metastatic castration-resistant prostate cancer who carry BRCA1/2 or ATM mutations. Presented by Dr. Maha H. A. Hussain at the 2026 ASCO GU Cancers Symposium, findings established that the combination therapy significantly outperformed monotherapies in overall survival and progression-free survival, highlighting the efficacy of upfront biomarker-selected treatment strategies.

Original Source(s)

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

  • by Julia Cipriano

  • May 5, 2026

Related Content

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min